• Disease
  • Type
  • Type 2
  • Type 2 Diabetes
  • David Richard Matthews

    Prominent publications by David Richard Matthews

    KOL Index score: 18767

    BACKGROUND: In the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, canagliflozin reduced the rates of major adverse cardiovascular events and the results suggested a renal benefit in patients with type 2 diabetes who were at high risk for cardiovascular events, compared with those treated with placebo. Here we report the results of a prespecified exploratory analysis of the long-term effects of canagliflozin on a range of sustained and adjudicated renal outcomes.

    METHODS: ...

    Also Ranks for: Type 2 Diabetes |  canagliflozin placebo |  canvas program |  renal outcomes |  cardiovascular events
    KOL Index score: 18327

    AIM: To examine the efficacy and safety of vildagliptin vs. glimepiride as add-on therapy to metformin in patients with type 2 diabetes mellitus in a 52-week interim analysis of a large, randomized, double-blind, multicentre study. The primary objective was to demonstrate non-inferiority of vildagliptin vs. glimepiride in glycosylated haemoglobin (HbA(1c)) reduction at week 52.

    METHODS: Patients inadequately controlled on metformin monotherapy (HbA(1c) 6.5-8.5%) and receiving a stable ...

    Also Ranks for: Metformin Monotherapy |  patients glimepiride |  hypoglycaemia vildagliptin |  diabetes mellitus |  type 2
    KOL Index score: 18323

    BACKGROUND: Early treatment intensification leading to sustained good glycaemic control is essential to delay diabetic complications. Although initial combination therapy has been suggested to offer more opportunities than a traditional stepwise approach, its validity remains to be determined.

    METHODS: Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of type 2 diabetes (VERIFY) was a randomised, double-blind, parallel-group study of newly diagnosed patients with ...

    Also Ranks for: Combination Therapy |  type 2 |  vildagliptin metformin |  glycaemic durability |  early treatment
    KOL Index score: 17080

    OBJECTIVE: To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors compared with metformin as monotherapy, or with other commonly used hypoglycaemic drugs combined with metformin, in adults with type 2 diabetes mellitus.

    DESIGN: Systematic review and meta-analysis of randomised controlled trials.

    DATA SOURCES: Medline, Embase, the Cochrane Library, conference proceedings, trial registers, and drug manufacturers' websites.

    ELIGIBILITY CRITERIA: Randomised controlled ...

    Also Ranks for: Dpp4 Inhibitors Hba1c |  metformin monotherapy |  2 diabetes |  systematic review metaanalysis |  treatment type
    KOL Index score: 16891

    OBJECTIVE: There are limited data about the effects of sodium-glucose cotransporter 2 inhibitors when used with insulin. We report the efficacy and safety of canagliflozin in patients with type 2 diabetes using insulin.

    RESEARCH DESIGN AND METHODS: The CANagliflozin CardioVascular Assessment Study is a double-blind, placebo-controlled study that randomized participants to placebo, canagliflozin 100 mg, or canagliflozin 300 mg once daily, added to a range of therapies. The primary end ...

    Also Ranks for: Insulin Therapy |  type 2 diabetes |  canagliflozin patients |  transporter 2 |  efficacy safety
    KOL Index score: 16545

    AIMS: To determine the prevalence of diabetes mellitus and pre-diabetes (impaired fasting glucose and impaired glucose tolerance) in adults in Sri Lanka. Projections for the year 2030 and factors associated with diabetes and pre-diabetes are also presented.

    METHODS: This cross-sectional study was conducted between 2005 and 2006. A nationally representative sample of 5000 adults aged >or= 18 years was selected by a multi-stage random cluster sampling technique. Fasting plasma glucose was ...

    Also Ranks for: Sri Lanka Diabetes |  cardiovascular study |  urban population |  glucose tolerance |  5000 adults
    KOL Index score: 16346

    OBJECTIVE: The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to metformin in subjects previously treated with oral antidiabetes (OAD) therapy.

    RESEARCH DESIGN AND METHODS: In this 26-week, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial, 1,091 subjects were randomly assigned (2:2:2:1:2) to once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day ...

    Also Ranks for: Glimepiride Placebo |  type 2 diabetes |  combination therapy metformin |  liraglutide groups |  3 months
    KOL Index score: 16170

    BACKGROUND: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that significantly reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and elevated cardiovascular risk. The comparative effects among participants with and without a history of cardiovascular disease (secondary versus primary prevention) were prespecified for evaluation.

    METHODS: The CANVAS Program (Canagliflozin Cardiovascular ...

    Also Ranks for: Secondary Prevention |  cardiovascular events |  canagliflozin placebo |  nonfatal stroke |  primary point
    KOL Index score: 15278

    OBJECTIVE: To determine the relation between systolic blood pressure over time and the risk of macrovascular or microvascular complications in patients with type 2 diabetes.

    DESIGN: Prospective observational study.

    SETTING: 23 hospital based clinics in England, Scotland, and Northern Ireland.

    PARTICIPANTS: 4801 white, Asian Indian, and Afro-Caribbean UKPDS patients, whether randomised or not to treatment, were included in analyses of incidence; of these, 3642 were included in analyses of ...

    Also Ranks for: Systolic Blood Pressure |  prospective observational study |  type 2 diabetes |  risk complications |  myocardial infarction
    KOL Index score: 14778

    Aims/hypothesis. To determine risk factors related to the incidence and progression of diabetic retinopathy over 6 years from diagnosis of Type II (non-insulin-dependent) diabetes mellitus. Methods. This report describes 1919 patients from within the United Kingdom Prospective Diabetes Study (UKPDS), with retinal photographs taken at diagnosis and 6 years later and with complete data available. Photographs were centrally graded for lesions of diabetic retinopathy using the modified Early ...

    Also Ranks for: 6 Years |  retinopathy diagnosis |  incidence progression |  type diabetes |  factors blood
    KOL Index score: 14706

    Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. Methods The CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive ...

    Also Ranks for: Type 2 Diabetes |  renal events |  canagliflozin cardiovascular |  hazard ratio |  trials patients
    KOL Index score: 14627

    AIMS: To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2 years in patients with type 2 diabetes.

    METHODS: In the 26-week the Liraglutide Effect and Action in Diabetes (LEAD)-2 core trial, patients (n = 1091) were randomized (2 : 2 : 2 : 1: 2) to liraglutide (0.6, 1.2 or 1.8 mg once-daily), placebo or glimepiride; all with metformin. Patients were enrolled if they were 18-80 years ...

    Also Ranks for: 2 Diabetes |  liraglutide glimepiride |  weight loss |  metformin patients |  combination therapy
    KOL Index score: 14496

    Aims/hypothesisThe aim of this analysis was to examine the long-term effects of pioglitazone or gliclazide addition to failing metformin monotherapy and pioglitazone or metformin addition to failing sulphonylurea monotherapy in patients with type 2 diabetes.MethodsTwo 2-year, randomised, multicentre trials were performed in patients with inadequately controlled type 2 diabetes (HbA1c 7.5–11% inclusive), who were receiving either metformin or a sulphonylurea at ≥50% of the maximum ...

    Also Ranks for: Metformin Patients |  2 diabetes |  addon therapy |  baseline hba1c |  pioglitazone addition
    KOL Index score: 14323

    BACKGROUND: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular death overall, in those with and without a baseline history of HF, and in other participant subgroups.

    METHODS: The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) enrolled 10 142 participants with type 2 diabetes mellitus and high cardiovascular risk. Participants were randomly assigned to ...

    Also Ranks for: Cardiovascular Death |  hf baseline |  heart failure |  diabetes mellitus |  type 2
    KOL Index score: 14107

    OBJECTIVE: To examine the correlates of patient and provider attitudes toward insulin therapy.

    RESEARCH DESIGN AND METHODS: Data are from surveys of patients with type 2 diabetes not taking insulin (n = 2,061) and diabetes care providers (nurses = 1,109; physicians = 2,681) in 13 countries in Asia, Australia, Europe, and North America. Multiple regression analysis is used to identify correlates of attitudes toward insulin therapy among patients, physicians, and nurses.

    RESULTS: Patient ...

    Also Ranks for: Insulin Therapy |  diabetes attitudes |  patients physicians |  north america |  resistance type


    David Richard Matthews: Influence Statistics

    Sample of concepts for which David Richard Matthews is among the top experts in the world.
    Concept World rank
    predisposing toxic environment #1
    detemir glar100 #1
    sotagliflozin blood glucose #1
    mellitus government #1
    ibw1min1 #1
    461±151 years #1
    retinopathy glucagon #1
    frequency circadian rhythm #1
    mediators 3 biomarkers #1
    regimens npl #1
    higher hdlc apoai #1
    diabetes oval #1
    increase insulin requirements #1
    26 iddm adolescents #1
    crs sri lankan #1
    canvas canvasr #1
    94112 #1
    new cases dpn #1
    glycaemia 1 reduction #1
    assessment study canagliflozin #1
    child hypertension obesity #1
    urbanicity physical inactivity #1
    ihoma2 #1
    3 pathogenesis #1
    effects rhigfi administration #1
    hba1clowering efficacy #1
    variation 92 #1
    metformin period #1
    fpg sri lankans #1
    insulin regime #1
    individual therapeutic decisions #1
    puberty diabetic adolescents #1
    day bolus injections #1
    pen‐sized glucose meter #1
    participants gada levels #1
    parenteral feeding controls #1
    vector slopes #1
    langerhans biological amino #1
    appreciation robert turner #1
    10 14 p00001 #1
    canvas programme #1
    diarrhoea tirzepatide #1
    nct01528254 #1
    glycaemic risk assessment #1
    life glimepiridemetformin #1
    canvas uacr #1
    intermittent pulsatility #1
    overview risks #1
    tirzepatide glp1 #1
    western province uva #1

    Key People For Type 2 Diabetes

    Top KOLs in the world
    David Richard Matthews
    type 2 diabetes sri lanka growth hormone
    Frank B Hu
    type 2 diabetes cardiovascular disease physical activity
    Rury R Holman
    type 2 diabetes cardiovascular disease impaired glucose tolerance
    David Matthew Nathan
    type 2 diabetes insulin resistance cardiovascular disease
    John B Buse
    type 2 diabetes insulin degludec cardiovascular outcomes
    Tuomilehto Tuomilehto
    type 2 diabetes blood pressure north karelia

    David Richard Matthews:Expert Impact

    Concepts for whichDavid Richard Matthewshas direct influence:Type 2 diabetes,  Sri lanka,  Type 2,  2 diabetes,  Growth hormone,  Insulin resistance,  Canvas program,  Sri lankan.

    David Richard Matthews:KOL impact

    Concepts related to the work of other authors for whichfor which David Richard Matthews has influence:Insulin resistance,  Type 2 diabetes,  Metabolic syndrome,  Glycemic control,  Blood pressure,  Heart failure,  Cardiovascular disease.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK | Harris Manchester College, University of Oxford, Oxford, UK | Oxford Centre for Diabetes, Endocrinology and Metabolism and Harris Manchester College, Universit